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1. Introduction 
The group agreed unanimously that at the present time, there are not enough data 
to recommend the use of concomitant or alternating RTKT in daily practice. Until 
information from current clinical trials becomes available, concomitant or alter- 
nating CT/RT schemes should be reserved for clinical research. Thus, the rest of the 
report will focus on clinical trials only. 
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2. Definition of concomitant and alternating regimen 
A therapeutic scheme can be defined as concomitant when chemotherapy is 
delivered at the same time as radiotherapy. In alternating schedules CT and RT are 
rapidly alternated, and integrated in such a way that they are not administered 
together but still in close proximity. It was felt that alternating schedules should be 
discussed in conjunction with concomitant regimens because of common 
characteristics, such as a rather short overall treatment time. 
3. Speeitie methods: defmitions and endpolnts relevant to concomitant or alternating 
RT/CT trials 
3.1. Minimum requirements for reporting CT 
There should be an exact description of the drug(s) with regard to dose, route of 
administration, exact duration (bolus vs. perfusion), time interval between CT and 
RT, report on dose intensity and supportive methods and therapies (antiemetics, 
antibiotics, growth factors, etc.). 
3.2. Minimum requirements for reporting RT 
There should be an exact description of the total dose, dose per fraction, daily 
dose (if more than 1 fraction/day), number of fractions, the interval between frac- 
tions, the number of treatment days per week, the total elapsed time, elective or un- 
forseen interruptions, description of the technique, methods of calculations, 
including lung corrections, and of the irradiated volumes, using ICRU 50 criteria. 
Volumes of normal tissues (e.g. lung), dose histograms and V/Q test, are recom- 
mended. 
3.3. ‘Minimum requirements for assessing response/control 
Chest X-rays are clearly insufficient and serial chest CAT scans should be obtain- 
ed (see also Endpoints Committee Report). 
3.4. Acute toxicity 
A universally accepted grading systems (e.g. NCMJICC) should be employed and 
clearly specified. At least all reactions equal or greater than Grade 3 should be 
recorded. 
3.5. Late complications/reactions 
These are defined as those that occur either after 90 days from the beginning of 
concomitant or alternated RT/CT or those occurring before but lasting beyond 90 
days. As for acute toxicity, accepted grading systems should be employed and 
specified. The rate of complications should be given using a time-adjusted method 
(i.e. actuarial calculations). A new NC1 late effects normal tissue (LENT) score 
which RTOG is developing with other cooperative groups is also being considered 
by EORTC and will be published soon. 
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3.6. Patterns of failure 
Relapse pattern is critical for evaluating the effect of a combined modality. The 
minimum requirement is to report failures at least at 3 levels: T, N and M, and 
preferably as a combination of these (giving a total of seven possible combinations) 
(see also Endpoints Committee Report). Ideally, whenever a site of failure (such as 
distant metastasis) is noted, the patient should be regularly investigated for other 
possible concurrent and later sites of failures (such as local). Toxic and intercurrent 
deaths are to be recorded. 
4. Current data 
A large number of Phase I-II studies on concomitant (and to a lesser extent alter- 
nating) RTKT have been published over the past 5 years, most of them using cispla- 
tin alone or cisplatin-based combination chemotherapy. Three non-cisplatin 
randomized trials failed to show any improvement when combined modality was 
compared with RT alone, whereas of four cisplatin randomized trials, only one 
demonstrated a benefit in local control and survival. It is felt that if there is any im- 
provement with concomitant CTiRT, it is modest and likely to be due to the use of 
cisplatin. 
5. Recommendations for future clinical trials 
5.1. Testing a chemotherapeutic agent as a radiosensitizer 
If a study is designed to assess the radiosensitizing effect of an agent, such as cis- 
platin, it is recommended that (i) it should be clearly specified, and (ii) the RT con- 
trol arm should correspond to a widely accepted current treatment (e.g. 60 Gy, 2 
Gy/fractions daily). 
5.2. Importance of local control (LC) 
Since the last meeting, one major emerging point is that even with high dose RT 
( f CT), local control is low (- 20%), certainly much lower than it had been thought 
previously, especially when local control was evaluated cytologically or histological- 
ly. Failing to achieve a local control is incompatible with cure. Since the majority 
(80%) of patients are not locally controlled, a CT regimen that would be efficient 
only on distant metastases would be of benefit in only on a minority of patients. Im- 
proving the local control is likely to have an effect on survival, and even possibly 
(according to recent models) on distant metastasis as well. 
5.3. Possible methods for improving local control 
In the context of concomitant or alternating treatment, LC could be improved by 
the following means: more agressive RT, currently tested multidrug combination CT 
with RT, new drugs and RT, cytokines and RT. 
5.4. Possible methods for improving local control 
In the context of concomitant or alternating treatments, LC could be improved 
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by the following means: more aggressive RT, currently tested multidrug combination 
of CT with RT, new drugs and RT, cytokines and RT. 
5.5. Improving RT 
Delivery of RT may be improved by newer technologies: 3D planning, conformal 
therapy, particle therapy, etc. Biological dose can be increased by the use of: new 
fractionations such as hyperfractionation, accelerated or hyperaccelerated fractiona- 
tion, dose escalation, combined external beam and endobronchial brachytherapy, 
radiosensitizers, etc. 
5.6. Current combinations of CT and RT 
There are enough Phase II studies (some with encouraging results) on combina- 
tion CTRT so that the currently best combinations (such as cisplatin-etoposide) 
should be tested with concomitant or alternating RT versus RT alone in Phase III 
randomized trials. 
5.7. New drugs and RT 
There are a number of new agents which are active in NSCLC (e.g. Taxol, Tax- 
otere, Navelbine, Edatrexate, Topotecan, CPT-11 and Gemcitabine) which should be 
tested first in Phase I concomitantly with RT, then in Phase II trials, with or without 
cisplatin. 
5.8. Cytokines with RT 
Amongst the various cytokines, some are known radiosensitizers and are being ac- 
tively investigated. Results of a pilot study using RT associated with b-interferon in 
very advanced cases of NSCLC have shown high efficacy and unexpected long-term 
survivals. A Phase III RTOG clinical trial is in progress. However, another pilot 
study investigating y-interferon and RT demonstrated substantial toxicity without 
apparent improvement in therapeutic index. 
Phase I trials on various interferons (e.g. a-interferon) with RT, both with or 
without cisplatin are encouraged. 
Other cytokines (interleukins, growth factors) may prove interesting, but the evi- 
dence is still anecdotal. 
5.9. Laboratory 
Research in cancer biology, such as cell kinetics, mechanisms of RT/CT resistance, 
interaction between chemical and biological radiation modifiers, should be actively 
pursued. Whenever results are found to be positive, concept should be further ex- 
plored using clinical Phase I trials. 
